Form 4: Pediatrix Director Thomas McEachin Receives Equity Grant

Director Thomas McEachin was granted 7,196 restricted shares of Pediatrix Medical Group, Inc. as part of an annual equity award.

Summary

• Director Thomas McEachin received an annual equity grant of 7,196 restricted shares of Pediatrix Medical Group, Inc. (MD).
• The shares were granted on May 7, 2026, at a price of $0 per share as part of the company's Amended and Restated 2008 Incentive Compensation Plan.
• Following this transaction, the director's direct beneficial ownership increased to 18,623 shares.
• The director also maintains an indirect interest in 54,646 shares held through the Thomas A. McEachin Living Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• The equity grant aligns the director's interests with those of shareholders through long-term stock ownership.
• The shares are subject to a one-year vesting period, ending May 7, 2027, which encourages retention.

Negatives

• None identified; this is a standard compensatory equity grant for a board member.

Risks

• The value of the equity grant is subject to market volatility and the future performance of Pediatrix Medical Group, Inc. stock.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that annual equity grants to board members are a standard corporate governance practice in the healthcare services sector to ensure alignment between directors and shareholders.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for director compensation is consistent with standard practices among mid-cap healthcare companies.
• The one-year vesting schedule is a common benchmark for annual director equity awards.

Corporate Governance

Related Party Transactions

• The director holds 54,646 shares through the Thomas A. McEachin Living Trust, for which he and his spouse are trustees.

Stakeholder Impact

• Minimal impact on shareholders; the grant is a standard component of director compensation.

Next Steps

• Vesting of the 7,196 restricted shares on May 7, 2027.

Key Dates

Keywords

Pediatrix Medical Group, MD, Form 4, Insider Trading, Equity Compensation, Director Ownership